Extent of regression dilution for established and novel coronary risk factors: results from the British Regional

Jonathan R Emberson1, Peter H Whincup, Richard W Morris

  • 1Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, NW3 2PF, UK. j.emberson@pcps.ucl.ac.uk

Insights

Using single measurements underestimates coronary heart disease (CHD) risk factors. Repeated measurements are crucial for accurate CHD risk assessment and prevention strategies.

Area of Science:

  • Cardiovascular Epidemiology
  • Biostatistics

Background:

  • Measurement error in risk factors causes underestimation of disease associations (regression dilution bias).
  • Established and novel risk factors for coronary heart disease (CHD) are examined for this bias.
  • Consequences for CHD prevention are considered.

Purpose of the Study:

  • To quantify regression dilution bias for CHD risk factors.
  • To assess the impact of this bias on CHD risk factor importance and prevention.

Main Methods:

  • Prospective study of middle-aged British men followed for 20 years.
  • Repeated measurements of blood lipids, blood pressure, insulin, homocysteine, and hemostatic factors at various intervals.

Main Results:

  • Single baseline measures significantly underestimate risk associations over time.
  • Total cholesterol showed 47% underestimation; diastolic blood pressure showed 76% underestimation in the third decade.
  • Regression dilution bias can misrepresent the importance of even precisely measured risk markers.

Conclusions:

  • Single baseline measures in prospective studies greatly underestimate the importance of CHD risk factors.
  • Accounting for regression dilution is essential for accurate estimation of usual exposure levels and disease risk.
  • Failure to address regression dilution leads to misinterpretation of CHD risk factor significance.
Abstract

Related Concept Videos

Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...